NCT05011045
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
Recruiting · Not specified · M.D. Anderson Cancer Center · registry updated 2026-05-20
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies). This may help researchers learn more about the effects of whole brain radiation therapy on memory and thinking in patients with blood cancer.
Inclusion
- Age 18 years or older
- Treatment with radiation therapy to the brain for a hematologic malignancy (ex. primary central nervous system lymphoma \[PCNSL\], secondary central nervous system lymphoma \[SCNSL\], leukemia, myeloma)
- Proficient and capable of completing tests in English
- Patients with claustrophobia are eligible if the claustrophobia is managed with medication
- Patients with cognitively-impairment are eligible if the impairment is managed with medication
- Patients who are pregnant